Medical news today: Tuesday, November 10, 2026
FDA approves asundexian for selected stroke survivors; early gene-editing lipid data emerge; preliminary AI echocardiogram study reports faster review
Get tomorrow's issue in your inbox.
- 01
FDA approves asundexian, the first US-approved Factor XIa inhibitor for selected patients after stroke or high-risk TIA
Source: US FDA
The FDA announced on November 9 that it had approved Sunharbo (asundexian) 50 mg once daily with antiplatelet therapy to reduce stroke risk in adults after a recent mild-to-moderate non-cardioembolic ischaemic stroke or a high-risk transient ischaemic attack. The decision was supported by the phase 3 OCEANIC-STROKE trial of 12,327 adults; the FDA reports a 26% reduction in ischaemic stroke versus placebo over a median 14.2 months. Overall major bleeding was similar between groups, but was higher with asundexian in patients older than 75 and during the first 90 days; gastrointestinal bleeding was more common and diarrhoea was the most frequent adverse reaction. The drug is not approved for stroke prevention in atrial fibrillation.
Why it mattersThis is a regulatory milestone for Factor XIa inhibition, but the indication is specific. Prescribers and safety teams need to attend to bleeding patterns, drug interactions, hepatic restrictions and peri-procedural withholding instructions in the FDA release rather than extrapolating the approval to other stroke mechanisms or atrial fibrillation. More on Approvals & regulatory →
- 02
Phase 1b CTX310 gene-editing study reports large triglyceride reductions in 10 adults
Source: Cleveland Clinic
Cleveland Clinic reported on November 9 that a phase 1b study of CTX310, an intravenous CRISPR-Cas9 therapy targeting ANGPTL3, included 10 adults with severe hypertriglyceridaemia. Thirty days after a single infusion, average triglycerides were 63% lower, with reductions up to 85%; ANGPTL3 levels fell by more than 65%. The investigators reported no serious treatment-related adverse effects in this small early study. The results were presented at the American Heart Association Scientific Sessions and do not establish long-term durability or cardiovascular benefit. The study was funded by CRISPR Therapeutics.
Why it mattersThe findings are an early proof-of-concept for gene editing in severe lipid disorders, not evidence of an established treatment. Longer follow-up is needed to assess durability, delayed risks, dose selection and whether biomarker changes translate into fewer pancreatitis or cardiovascular events. More on Drug & device safety →
- 03
AI-assisted echocardiogram drafts cut cardiologists’ review time by about 46% in a preliminary trial
Source: American Heart Association
The American Heart Association reported on November 9 that a randomized study compared AI-generated preliminary reports with sonographer- and cardiologist-prepared drafts for 1,200 echocardiograms from 21 Kaiser Permanente Northern California medical centres. Cardiologists made substantial changes to 50.6% of AI drafts versus 49.7% of human-prepared drafts, meeting the study's non-inferiority criterion. Average review and finalisation time was 4.6 minutes with AI drafts versus 8.5 minutes without them, a reduction of about 46%. The results were presented as a late-breaking conference abstract and have not yet been peer-reviewed.
Why it mattersThe study suggests AI may reduce reporting workload while keeping a cardiologist responsible for the final interpretation. It did not test long-term patient outcomes, and the authors say larger real-world evaluations are needed before assuming the time savings or accuracy will generalise. More on Journal papers →
More recent digests
- Wednesday, November 18, 2026White House pulls its FDA nominee, the US loses measles elimination status, and FDA offers to share its approval reviews with other regulators
- Tuesday, November 17, 2026US flu deaths in children rise, a Cochrane review backs daily iron for anaemia, and the FDA approves giredestrant for selected breast cancers
- Monday, November 16, 2026Teen tirzepatide trial cuts BMI, US flu season starts early, and the FDA rejects Summit's lung cancer drug
- Sunday, November 15, 2026WHO issues first type 1 diabetes guidance for adults and children; JAMA reports a possible CTE blood biomarker; MP flags mercury creams
- Saturday, November 14, 2026FDA approves a weekly self-injected myasthenia gravis drug; US measles deaths rise; India enforces lower cancer-drug prices
- Friday, November 13, 2026WHO reports persistent TB burden; JAMA publishes new oncology and neonatal sepsis trials; MHRA flags a packaging defect
- Thursday, November 12, 2026WHO reports continuing Ebola emergency and African regulatory advances; FDA approves first FXIa inhibitor for secondary stroke prevention
Free daily email
The day's approvals, safety signals and trials, in five minutes.
Join the list with just your email. You can also follow the RSS feed.
